Diffuse large B-cell lymphoma (DLBCL) account for approximately 40% of adult non-Hodgkin lymphomas. It is clinically, morphologically and genetically a heterogeneous group of tumors composed of large ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...

Diffuse lymphomas of B-cell origin represent a heterogeneous group of lymphoid neoplasms. The histologically aggressive subtypes of diffuse B-cell lymphomas include biologically different entities, ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

You have several treatment options if you have B-cell lymphoma. Your doctor will go over the choices, including chemotherapy, radiation, and immunotherapy. Which treatment you and your doctor pick ...